ASX:TLXBiotechs
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch
Telix Pharmaceuticals (ASX:TLX) has drawn fresh investor attention after Regeneron agreed to a US$40 million upfront payment to access its radiopharmaceutical platform, alongside Telix starting the pivotal Phase 3 IPAX BrIGHT trial in recurrent glioblastoma.
See our latest analysis for Telix Pharmaceuticals.
Against this backdrop, Telix’s recent news is landing on a share price that has gained 15.76% over the past 30 days and 28.46% over 90 days, while the 1 year total shareholder return...